SHANGHAI – At the recent China Healthcare Investment Conference (CHIC) – where investors and Chinese biotech CEOs meet up to try and make their investment dreams come true – the theme was growth vs. innovation. Whether innovation stems from growth or growth comes from other drivers, both appear to be significantly helped along by the recent spate of CFDA regulatory reforms.